NeuroSense’s Phase IIa study with PrimeC in ALS patients has been completed successfully, and shows safety and tolerability. Additionally, NeuroSense is granted patent allowance in the US.

 

NeuroSense receives orphan drug designation from the European Medicines Agency (EMA), for the treatment of ALS patients with PrimeC.

 

Read about how NeuroSense began, how we got to where we are today, and what our plans are moving forward.

 

 

 

 

 

 

Learn more about NeuroSense, PrimeC and clinical trial results from our presentation at the ALS/MND Symposium.

 

NeuroSense’s trial in Tel Aviv continues with its promising trends at the 9-month treatment analysis.

 

Hear the people of NeuroSense discuss the science behind our drug, and present pre-clinical and preliminary clinical results.

 

Opening: 0:21

Introduction to NeuroSense’s Story: 3:40

PrimeC Mechanism of Action: 9:02

Pre-Clinical Results: 14:45

Pre-Clinical results summary: 24:56

PrimeC Unique Formulation: 26:57

Clinical Study NST002 Interim Top-Line Results: 29:14

Next Steps: 37:32

Q&A: 38:29

 

Two of the women behind NeuroSense Therapeutics share their life stories and discuss the special value of women in the scientific world.

 

Read about the promising preliminary results of our clinical trial in ALS patients.

 

NeuroSense kicks off two clinical trials in three sites in the US and Israel, and receives orphan drug designation from the FDA, for the treatment of ALS with PrimeC.

 

Ariel Gordon and Yossi Gross, two of our investors, talk about the reasons that led them to play an active role in developing a cure for ALS.

 

NeuroSense Therapeutics CEO, Alon Ben-Noon, discusses ALS, our drug PrimeC, and the novel ALS zebrafish model.

 

The amazing story about how Dr. Niva Russek-Blum, the scientist who spent years screening hundreds of potential drugs for ALS, to no avail, finally found a high-efficacy combination drug in collaboration with NeuroSense Therapeutics.